Atricure Inc (ATRC) valuation
Atricure P/E ratio history
Atricure trades at 291.7 times its earnings over the last twelve months and 170.7 times the earnings analysts expect over the next twelve.
| Fiscal year ended | Price | EPS | P/E |
|---|---|---|---|
| Dec 31, 2025 | $39.56 | -$0.24 | n/m |
| Dec 31, 2024 | $30.56 | -$0.95 | n/m |
| Dec 31, 2023 | $35.69 | -$0.66 | n/m |
| Dec 31, 2022 | $44.38 | -$1.02 | n/m |
| Dec 31, 2021 | $69.53 | $1.09 | 63.8 |
| Dec 31, 2020 | $55.67 | -$1.16 | n/m |
| Dec 31, 2019 | $32.51 | -$0.94 | n/m |
| Dec 31, 2018 | $30.60 | -$0.63 | n/m |
| Dec 31, 2017 | $18.24 | -$0.83 | n/m |
| Dec 31, 2016 | $19.57 | -$1.05 | n/m |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Atricure valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| AtricureATRC | $3.10B | 291.7 | 170.7 | 5.5 |
| Disc MedicineIRON | $3.09B | — | — | — |
| Surgery PartnersSGRY | $3.04B | — | 82.2 | 0.9 |
| Denali TherapeuticsDNLI | $3.01B | — | — | 834.1 |
| Amylyx PharmaceuticalsAMLX | $3.21B | — | — | — |
| National HealthcareNHC | $3.22B | 23.2 | — | 2.1 |
| Tarsus PharmaceuticalsTARS | $3.22B | — | — | 5.3 |
| Tango TherapeuticsTNGX | $3.29B | — | — | 61.1 |
| Aveanna HealthcareAVAH | $2.87B | 10.4 | 15.2 | 1.1 |
| Peer median | 16.8 | 48.7 | 3.7 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: ATRC financials · ATRC returns
No forecast, no recommendation. This page describes Atricure Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.